| Document |
Document Title |
|
WO/2006/019685A2 |
The present invention provides novel ginsenoside compounds, compositions (e.g. pharmaceutical compositions) comprising the ginsenoside compounds, and methods for the synthesis of these ginsenoside compounds. Additionally, the present inv...
|
|
WO/2005/116042A1 |
The present invention relates to ginsenoside derivatives effective in prevention and treatment of cancer. More specifically, the present invention relates to ginsenoside derivatives with novel structures effective in prevention and treat...
|
|
WO/2005/116049A1 |
A method for selectively separating desirable steroidal glycosides from undesirable components present in plant material of the Asclepiadaceae family containing the same. The method comprises contacting the plant material or material der...
|
|
WO/2005/095436A1 |
3-O-β-D-Glucopyranosyl-4-methylerogst-7-en-3-ol or an extract of a liliaceae plant or a fraction thereof containing this compound, which is a composition containing 0.001% by mass or more of the above compound, is used as the active ing...
|
|
WO/2005/084689A1 |
The invention discloses a Radix astragli extract and production method and use thereof. Such Radix astragli extract mainly comprises astragalus saponin, organic acid and astragalus flavonoid glycoside. Such production method consists of ...
|
|
WO/2005/042033A1 |
The present invention is directed to novel chemical agents for compounds and their use for imaging myocardial perfusion. The invention also is directed to a kit for forming such novel agents. The chemical agents for the present invention...
|
|
WO/2005/040189A1 |
This invention relates to a group of novel dammarane sapogenin compounds and their use in anti-cancer applications. More particularly, this invention pertains to a novel group of dammarane sapogenin: PPD derivative 1, 2, 3, 4 and PPT der...
|
|
WO/2005/007172A1 |
A medical preparation which can maximize the effect of a cholestanol glycoside useful as an antitumor agent. It is a liposome which comprises: a hydrophobic-compound glycoside having an antitumor activity, having GlcNAc-Gal-, GlcNAc-Gal-...
|
|
WO/2004/098538A2 |
The invention describes novel nitrosated and/or nitrosylated compounds of the invention, and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound of the inventi...
|
|
WO/2004/092329A2 |
The present invention discloses novel saponin derivatives for use with nucleic acids that induce an immune response when administered to animals and humans. The novel saponin derivatives disclosed comprise (a) a saponin aglycone core, wh...
|
|
WO/2004/058796A1 |
There are provided a promoter containing ginsenoside compound K for the production of hyaluronic acid, and more particularly, a new efficacy of 20-O-β-D-glucopyranosyl-20(S)-protopanaxadiol (compound K), a chief metabolite of ginseng sa...
|
|
WO/2004/028475A2 |
Glycosylceramide analogues are disclosed in which the ceramide moiety and optionally the carbohydrate moiety are modified or replaced. These analogues are useful as immunomodulators, antitumor agents, and as other pharmaceutical agents.
|
|
WO/2004/024745A2 |
There is provided a crystalline chemical complex comprising a compound of formula (I) in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in the crystalline complex is of space group P212121 havi...
|
|
WO/2004/017904A2 |
The invention features corticosteroids conjugated to either a charged group or a bulky group in a manner that resists in vivo cleavage, the resulting conjugate is a peripherally acting steroid with reduced activity in the central nervous...
|
|
WO/2004/009613A1 |
There is provided a crystalline chemical complex comprising a compound of formula (I) in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in that the crystalline complex is of space group P212121...
|
|
WO/2004/005313A2 |
The present invention relates (a) to new compounds represented by Formula I wherein M represents a macrocode subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, V represents an...
|
|
WO/2003/104254A2 |
The present invention provides novel derivatives comprising compounds in the androstane and androstene series, coupled with ascorbic acid, including salts thereof, and represented by one or more of the general formulae (I), (II), (III): ...
|
|
WO/2003/075931A1 |
A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in an animal comprises administering a non-toxic and therapeutically effective amount of one or more of the following compounds: formula (I,...
|
|
WO/2003/066655A1 |
According to one aspect of the invention, there is provided a compound of formula (I) in the form of a substantially amorphous solid.
|
|
WO/2003/066026A1 |
There is provided according to the invention a pharmaceutical formulation comprising an aqueous carrier liquid having dissolved therein: (a) a glucocorticoid of formula (I), wherein R represents ethyl or a 5 membered heterocyclic aromati...
|
|
WO/2003/066032A1 |
There is provided a pharmaceutical aerosol formulation comprising (i) a compound of formula (I) or a solvate thereof as medicament, (ii) a liquified hydrofluoroalkane (HFA) gas as propellant; and characterised in that the compound of for...
|
|
WO/2003/066036A1 |
According to one aspect of the invention, there is provided a pharmaceutical formulation for administration by inhalation comprising a compound of formula (I), or a solvate thereof, together with a long−acting β2−adrenoreceptor agon...
|
|
WO/2003/066656A1 |
There is provided a crystalline complex comprising a compound of formula (I) in which the crystal lattice is stabilised by the presence of a guest molecule, characterised in that the crystalline complex is of space group P212121 having u...
|
|
WO/2003/066024A1 |
There is provided a pharmaceutical formulation comprising an aqueous suspension of particulate compound of formula (I) or a solvate thereof.
|
|
WO/2003/064445A1 |
A compound of formula (I): wherein R1 represents C1-6 alkyl or C1-6 haloalkyl; R2 represents a 5 membered heterocyclic aromatic ring containing 1-3 heteroatoms selected from O, N and S optionally substituted with one or more methyl group...
|
|
WO/2003/062259A2 |
A compound of formula (I); wherein R1 represents represents C1-6 alkyl or C1-6 haloalkyl; R2 represents a 4-7 membered non-aromatic ring containing 1-3 heteroatoms selected from O, N and S optionally substituted with one or more methyl o...
|
|
WO/2003/043640A2 |
The present invention relates to a method for the treatment of a patient suffering from major depressive disorder by administering to the patient an effective amount of a glucocorticoid receptor antagonist and to methods for establishing...
|
|
WO/2003/035668A2 |
Novel Anti-inflammatory Androstane DerivativesThere are provided compounds of formula (I) wherein R1 represents O, S or NH;R2 represents -C(&equals O)-aryl or -C(&equals O)-heteroaryl;R3 represents hydrogen, methyl (which may be in eithe...
|
|
WO/2003/022866A1 |
A cholesterol derivative represented by the following general formula (1), which specifically bonds to ß2−glycoprotein. By using this derivative, ß2−glycoprotein or the like can be highly practically determined. Based on this deter...
|
|
WO/2003/010182A1 |
This invention relates to a group of novel sapogenins, their use in anti-cancer applications, and to a process for their production. More particularly, this invention pertains to a novel group of dammarane sapogenins, PAM-120, PBM-110 an...
|
|
WO/2002/100879A1 |
There are provided compounds of formula (I) wherein R¿1? represents C¿1-6? alkyl or C¿1-6? haloalkyl; R¿2? represents a 4-7 membered non-aromatic ring containing 1-3 heteroatoms selected from O, N and S optionally substituted with on...
|
|
WO/2002/094284A1 |
22,29-epoxy-3,4,6,7,29-pentahydroxy-,(3$g(a),4$g(b),5$g(a),6
$g(a),7$g(b),14$g(b),22S)-stigmastan-15-one is useful for treating dry eye disorders and other disorders requiring the wetting of the eye.
|
|
WO2001042273A9 |
This invention relates to methods for treating asthma or allergy in a mammal by administering a 3-aminosteroid compound to a mammal in need thereof. The 3-aminosteroid compound being capable of down regulating the IL-9 pathway and allevi...
|
|
WO/2002/079219A2 |
The present invention is based on the finding that 6-O-acyl-beta-D-glucosyl-beta-sitosterols extracted from fig latex were effective in inhibiting cell proliferation and thus may be used as anti-proliferative agents for the treatment of ...
|
|
WO/2002/072599A1 |
Efficacious intravenous preparations, skin preparations for external use, mucosal preparations for external use or cosmetics comprising novel ginsenoside derivatives (in particular, dihydroxyginsenoside Rb¿1? or epoxyginsenoside Rb¿1?)...
|
|
WO/2002/069977A1 |
The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy...
|
|
WO2001032679A9 |
A novel glycoside compound for use in treating or preventing cardiovascular disease and it's underlying conditions such as atherosclersis and hypercholeterolemia comprises a carbohydrate moiety and a non-carbohydrate moiety wherein the c...
|
|
WO2002019971A9 |
The invention relates to 17-Methylene steroids. Method for the production thereof and pharmaceutical compositions containing these compounds. The inventive compounds have an active profile with a hybrid character of such that they act as...
|
|
WO/2002/055529A2 |
A method for recovering soy saponis which comprises extracting a soy isoflavone concentrate derived from soy molasses with a mixture of acetone and water, removing undissolved solids from the extract, cooling the extract such that soy sa...
|
|
WO/2002/055531A1 |
The present invention relates to novel compounds represented by the structure I and pharmaceutical preparations thereof for the treatment of inflammatory diseases in humans and animals.
|
|
WO/2002/038166A2 |
The present invention relates to methods and compositions for the use in treating type 2 diabetes and obesity. More specifically, the invention relates to the methods of screening for the active compound from berries from plants of the P...
|
|
WO/2002/012266A1 |
There are provided according to the invention compounds of formula (I) wherein R¿1? represents C¿1-6? alkyl or C¿1-6? haloalkyl; R¿2? represents -C(=O)-aryl or -C(=O)-heteroaryl; R¿3? represents hydrogen, methyl (which may be in eit...
|
|
WO/2002/012265A1 |
According to one aspect of the invention, there is provided a compound of formula (I) and solvates thereof. There are also provided compositions containing the compound, processes for preparing it, and its use in therapy.
|
|
WO/2002/008243A1 |
The present invention relates inter alia to a novel oxidation process for the synthesis of a known intermediate, useful in the preparation of anti-inflammatory steroids, the known intermediate being of formula (I).
|
|
WO/2002/000679A2 |
Compounds of formula (I), where R is a monovalent cyclic organic group having from 3 to 15 atoms in the ring system, useful as pharmaceuticals.
|
|
WO/2001/098322A1 |
The present invention comprises the design, synthesis and development of a new class of chemotherapeutic agents for prophylactic and therapeutic treatments in a mammal, particularly a human, believed to be at risk of suffering from a hor...
|
|
WO/2001/092289A1 |
Efficacious intravenous preparations, skin preparations for external use, mucosal preparations for external use or cosmetics comprising ginsenosides, in particular, ginsenoside Rb or its derivative which are useful as skin tissue regener...
|
|
WO/2001/079256A1 |
A 19-norbufalin derivative compound of formula (I) and isomers pharmaceutically acceptable salts thereof. Compounds of formula (I) are Na?+¿,K?+¿-ATPase inhibitors and can be used in the treatment of cardiac and/or vascular malfunction...
|
|
WO/2001/049704A1 |
The present invention relates to the compounds of formula (I), a method for extracting it and a pharmaceutical composition containing it. The said extracting method includes: extracting the corpus radicis and/or radix fibrosa of a ginsen...
|
|
WO/2001/030802A2 |
The present invention provides methods and compositions to prevent or treat a hematopoietic disorder such as thrombocytopenia or neutropenia by administering to a subject an effective amount of a steroid such as 3,7,16,17-tetrahydroxy-an...
|
